TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: DAPK1 has also been associated with resistance to imatinib in chronic myeloid leukemia (Guru et al., 2022), autophagia (Singh et al., 2016), alterations in the p53 signaling pathway in chronic lymphocytic leukemia (Wang et al., 2014) and methylated in myelodysplastic syndrome (Greco et al., 2010).